Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

Bibliography

• National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and. stratification. Am J Kidney Dis 2002;39:S1-266
   Google Scholar
• National Kidney Foundation. KDOQI Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49:S12-154
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 2012;60:850-86
   PubMed Web of Science ®Google Scholar
• Detournay B, Simon D, Guillausseau PJ, Chronic kidney disease in type 2 diabetes patients in France: prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes. Diabetes Metab 2012;38:102-12
   PubMed Web of Science ®Google Scholar
• de Boer IH, Rue TC, Hall YN, Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532-9
   PubMed Web of Science ®Google Scholar
• Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 2009;31:2608-17
   PubMed Web of Science ®Google Scholar
• Whaley-Connell A, Sowers JR, McCullough PA, Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 2009;53:S11-21
   PubMed Web of Science ®Google Scholar
• Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000;26(Suppl 4):73-85
   PubMedGoogle Scholar
• Reilly JB, Berns JS. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease. Semin Dial 2010;23:163-8
   PubMed Web of Science ®Google Scholar
• Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis 2007;50:865-79
   PubMed Web of Science ®Google Scholar
• Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med 2011;123:133-43
   PubMed Web of Science ®Google Scholar
• Ritz E. Limitations and future treatment options in type 2 diabetes with renal impairment. Diabetes Care 2011;34(Suppl 2):S330-4
   PubMedGoogle Scholar
• Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab 2011;12:57-69
   PubMed Web of Science ®Google Scholar
• Ahmed Z, Simon B, Choudhury D. Management of diabetes in patients with chronic kidney disease. Postgrad Med 2009;121:52-60
   PubMed Web of Science ®Google Scholar
• Slinin Y, Ishani A, Rector T, Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. Am J Kidney Dis 2012;60:747-69
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Medications in the kidney. Acta Clin Belg 2008;63:76-80
   PubMed Web of Science ®Google Scholar
• Haneda M, Morikawa A. Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how? Nephrol Dial Transplant 2009;24:338-41
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Lefebvre PJ. Oral antidiabetic agents. A guide to selection. Drugs 1998;55:225-36
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother 2009;7:324-42
   PubMed Web of Science ®Google Scholar
• Rigalleau V, Beauvieux MC, Gonzalez C, Estimation of renal function in patients with diabetes. Diabetes Metab 2011;37:359-66
   PubMed Web of Science ®Google Scholar
• McFarland MS, Markley BM, Zhang P, Evaluation of modification of diet in renal disease study and Cockcroft-Gault equations for sitagliptin dosing. J Nephrol 2012;25:515-22
   PubMed Web of Science ®Google Scholar
• Luft D, Schmulling RM, Eggstein M. Lactic acidosis in biguanide-treated diabetics: a review of 330 cases. Diabetologia 1978;14:75-87
   PubMed Web of Science ®Google Scholar
• Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf 2010;33:727-40
   PubMed Web of Science ®Google Scholar
• Holstein A, Stumvoll M. Contraindications can damage your health–is metformin a case in point? Diabetologia 2005;48:2454-9
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Paquot N. Metformin revisited: a critical review of the benefit/risk balance in “at risk” patients with type 2 diabetes. Diabetes Metab 2013; Submitted
   PubMedGoogle Scholar
• Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359-71
   PubMed Web of Science ®Google Scholar
• Graham GG, Punt J, Arora M, Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50:81-98
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Vormfelde SV, Balen D, The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009;86:299-306
   PubMed Web of Science ®Google Scholar
• Stocker SL, Morrissey KM, Yee SW, The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther 2013;93:186-94
   PubMed Web of Science ®Google Scholar
• Sirtori CR, Franceschini G, Galli-Kienle M, Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther 1978;24:683-93
   PubMed Web of Science ®Google Scholar
• Tucker GT, Casey C, Phillips PJ, Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981;12:235-46
   PubMed Web of Science ®Google Scholar
• Sambol NC, Chiang J, Lin ET, Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 1995;35:1094-102
   PubMed Web of Science ®Google Scholar
• Lalau JD, Vermersch A, Hary L, Type 2 diabetes in the elderly: an assessment of metformin (metformin in the elderly). Int J Clin Pharmacol Ther Toxicol 1990;28:329-32
   PubMedGoogle Scholar
• Frid A, Sterner GN, Londahl M, Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care 2010;33:1291-3
   PubMed Web of Science ®Google Scholar
• Duong JK, Roberts DM, Furlong TJ, Metformin therapy in patients with chronic kidney disease. Diabetes Obes Metab 2012;14:963-5
   PubMed Web of Science ®Google Scholar
• Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1431-7
   PubMed Web of Science ®Google Scholar
• Lalau JD, Andrejak M, Moriniere P, Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. Int J Clin Pharmacol Ther Toxicol 1989;27:285-8
   PubMedGoogle Scholar
• Dichtwald S, Weinbroum AA, Sorkine P, Metformin-associated lactic acidosis following acute kidney injury. Efficacious treatment with continuous renal replacement therapy. Diabet Med 2012;29:245-50
   PubMed Web of Science ®Google Scholar
• Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999;20:489-503
   PubMed Web of Science ®Google Scholar
• Harrower AD. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 1996;31:111-19
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Metformin and lactic acidosis. Acta Clin Belg 2011;66:329-31
   PubMed Web of Science ®Google Scholar
• Philbrick AM, Ernst ME, McDanel DL, Metformin use in renal dysfunction: is a serum creatinine threshold appropriate? Am J Health Syst Pharm 2009;66:2017-23
   PubMed Web of Science ®Google Scholar
• Emslie-Smith AM, Boyle DI, Evans JM, Contraindications to metformin therapy in patients with Type 2 diabetes–a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18:483-8
   PubMed Web of Science ®Google Scholar
• Vasisht KP, Chen SC, Peng Y, Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab 2010;12:1079-83
   PubMed Web of Science ®Google Scholar
• Pongwecharak J, Tengmeesri N, Malanusorn N, Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome. Pharm World Sci 2009;31:481-6
   PubMed Web of Science ®Google Scholar
• Kennedy L, Herman WH. Renal status among patients using metformin in a primary care setting. Diabetes Care 2005;28:922-4
   PubMed Web of Science ®Google Scholar
• Roussel R, Travert F, Pasquet B, Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010;170:1892-9
   PubMed Web of Science ®Google Scholar
• Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract 2011;118:c380-3
   PubMed Web of Science ®Google Scholar
• Pilmore HL. Review: metformin: potential benefits and use in chronic kidney disease. Nephrology (Carlton) 2010;15:412-18
   PubMed Web of Science ®Google Scholar
• del Pozo-Fernandez C, Pardo-Ruiz C, Sanchez-Botella C, Discrepancies among consensus documents, guidelines, clinical practice and the legal framework for the treatment of type 2 diabetes mellitus patients. Nefrologia 2012;32:367-73
   PubMed Web of Science ®Google Scholar
• Rocha A, Almeida M, Santos J, Metformin in patients with chronic kidney disease: strengths and weaknesses. J Nephrol 2013;26:55-60
   PubMed Web of Science ®Google Scholar
• Inkster B, Zammitt NN, Frier BM. Drug-induced hypoglycaemia in type 2 diabetes. Expert Opin Drug Saf 2012;11:597-614
   PubMed Web of Science ®Google Scholar
• Schejter YD, Turvall E, Ackerman Z. Characteristics of patients with sulphonylurea-induced hypoglycemia. J Am Med Dir Assoc 2012;13:234-8
   PubMed Web of Science ®Google Scholar
• Holstein A, Hammer C, Hahn M, Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Expert Opin Drug Saf 2010;9:675-81
   PubMed Web of Science ®Google Scholar
• Moen MF, Zhan M, Hsu VD, Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1121-7
   PubMed Web of Science ®Google Scholar
• Hung AM, Roumie CL, Greevy RA, Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int 2012;81:698-706
   PubMed Web of Science ®Google Scholar
• Rosenkranz B. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Horm Metab Res 1996;28:434-9
   PubMed Web of Science ®Google Scholar
• Balant L. Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs. Clin Pharmacokinet 1981;6:215-41
   PubMed Web of Science ®Google Scholar
• Ueda H, Sakurai T, Ota M, Disappearance rate of tolbutamide in normal subjects and in diabetes mellitus, liver cirrhosis, and renal disease. Diabetes 1963;12:414-19
   PubMed Web of Science ®Google Scholar
• Petitpierre B, Perrin L, Rudhardt M, Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy. Int J Clin Pharmacol 1972;6:120-4
   PubMedGoogle Scholar
• Rydberg T, Jonsson A, Roder M, Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 1994;17:1026-30
   PubMed Web of Science ®Google Scholar
• Pearson JG, Antal EJ, Raehl CL, Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function. Clin Pharmacol Ther 1986;39:318-24
   PubMed Web of Science ®Google Scholar
• Jonsson A, Rydberg T, Sterner G, Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 1998;53:429-35
   PubMed Web of Science ®Google Scholar
• Brier ME, Bays H, Sloan R, Pharmacokinetics of oral glyburide in subjects with non-insulin-dependent diabetes mellitus and renal failure. Am J Kidney Dis 1997;29:907-11
   PubMed Web of Science ®Google Scholar
• van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735-41
   PubMed Web of Science ®Google Scholar
• Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 2000;35:500-5
   PubMed Web of Science ®Google Scholar
• Weir MA, Gomes T, Mamdani M, Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: a population-based nested case-control study. Nephrol Dial Transplant 2011;26:1888-94
   PubMed Web of Science ®Google Scholar
• Aspinall SL, Zhao X, Good CB, Intervention to decrease glyburide use in elderly patients with renal insufficiency. Am J Geriatr Pharmacother 2011;9:58-68
   PubMed Web of Science ®Google Scholar
• Rosenkranz B, Profozic V, Metelko Z, Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996;39:1617-24
   PubMed Web of Science ®Google Scholar
• Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001;17:467-73
   PubMed Web of Science ®Google Scholar
• Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics and pharmacodynamics of glipizide in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1983;21:98-107
   PubMedGoogle Scholar
• Balant L, Zahnd G, Gorgia A, Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia 1973;331-8
   PubMed Web of Science ®Google Scholar
• Arjona Ferreira JC, Marre M, Barzilai N, Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care 2012; published on line 2012/12/19; doi: 10.2337/dc12-1365
   PubMed Web of Science ®Google Scholar
• Arjona Ferreira JC, Corry D, Mogensen CE, Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis 2013; published on line 2013/01/29; doi: 10.1053/j.ajkd.2012.11.043
   Web of Science ®Google Scholar
• Campbell DB, Gordon BH, Ings RMJ, The effect of renal disease on the pharmacokinetics of gliclazide in diabetic patients. Br J Clin Pharmacol 1986;21:572-3
   Google Scholar
• Zanchi A, Lehmann R, Philippe J. Antidiabetic drugs and kidney disease–recommendations of the Swiss Society for Endocrinology and Diabetology. Swiss Medl Wkly 2012;142:w13629
   PubMed Web of Science ®Google Scholar
• Drouin P, Standl E. Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes. Diabetes Obes Metab 2004;6:414-21
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Grimaldi A, Di Mario U, GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34:535-42
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• Malaisse WJ. Gliquidone contributes to improvement of type 2 diabetes mellitus management: a review of pharmacokinetic and clinical trial data. Drugs R D 2006;7:331-7
   PubMedGoogle Scholar
• Scott LJ. Repaglinide: a review of its use in type 2 diabetes mellitus. Drugs 2012;72:249-72
   PubMed Web of Science ®Google Scholar
• McLeod JF. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet 2004;43:97-120
   PubMed Web of Science ®Google Scholar
• Schumacher S, Abbasi I, Weise D, Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 2001;57:147-52
   PubMed Web of Science ®Google Scholar
• Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003;26:886-91
   PubMed Web of Science ®Google Scholar
• Devineni D, Walter YH, Smith HT, Pharmacokinetics of nateglinide in renally impaired diabetic patients. J Clin Pharmacol 2003;43:163-70
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 2007;46:93-108
   PubMed Web of Science ®Google Scholar
• Marbury TC, Ruckle JL, Hatorp V, Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 2000;67:7-15
   PubMed Web of Science ®Google Scholar
• Inoue T, Shibahara N, Miyagawa K, Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 2003;60:90-5
   PubMed Web of Science ®Google Scholar
• Nagai T, Imamura M, Iizuka K, Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract 2003;59:191-4
   PubMed Web of Science ®Google Scholar
• Abe M, Okada K, Maruyama T, Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis. Endocr J 2010;57:579-86
   PubMed Web of Science ®Google Scholar
• Balfour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993;46:1025-54
   PubMed Web of Science ®Google Scholar
• Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs 2000;59:521-49
   PubMed Web of Science ®Google Scholar
• Abe M, Kikuchi F, Kaizu K, Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis. Clin Nephrol 2007;68:287-94
   PubMed Web of Science ®Google Scholar
• Abe M, Okada K, Maruyama T, Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother 2010;11:169-76
   PubMed Web of Science ®Google Scholar
• Iglesias P, Diez JJ. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur J Endocrinol 2006;154:613-21
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 2006;70:1223-33
   PubMed Web of Science ®Google Scholar
• Tolman KG. The safety of thiazolidinediones. Expert Opin Drug Saf 2011;10:419-28
   PubMed Web of Science ®Google Scholar
• Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf 2007;30:741-53
   PubMed Web of Science ®Google Scholar
• Betteridge DJ. Thiazolidinediones and fracture risk in patients with Type 2 diabetes. Diabet Med 2011;28:759-71
   PubMed Web of Science ®Google Scholar
• Ramirez SP, Albert JM, Blayney MJ, Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol 2009;20:1094-101
   PubMed Web of Science ®Google Scholar
• Brunelli SM, Thadhani R, Ikizler TA, Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. Kidney Int 2009;75:961-8
   PubMed Web of Science ®Google Scholar
• Manley HJ, Allcock NM. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy 2003;23:861-5
   PubMed Web of Science ®Google Scholar
• Fritsche L, Budde K, Glander P, Treating type 2 diabetes in renal insufficiency: the role of pioglitazone. Int J Clin Pharmacol Ther 2003;41:488-91
   PubMed Web of Science ®Google Scholar
• Budde K, Neumayer HH, Fritsche L, The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003;55:368-74
   PubMed Web of Science ®Google Scholar
• Abe M, Kikuchi F, Okada K, Plasma concentration of pioglitazone in patients with type 2 diabetes on hemodialysis. Ther Apher Dial 2009;13:238-9
   PubMed Web of Science ®Google Scholar
• Abe M, Okada K, Maruyama T, Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother 2010;11:1611-20
   PubMed Web of Science ®Google Scholar
• Schneider CA, Ferrannini E, Defronzo R, Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 2008;19:182-7
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Outcomes and lessons from the PROactive study. Diabetes Res Clin Pract 2012;98:175-86
   PubMed Web of Science ®Google Scholar
• Cox PJ, Ryan DA, Hollis FJ, Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000;28:772-80
   PubMed Web of Science ®Google Scholar
• Chapelsky MC, Thompson-Culkin K, Miller AK, Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 2003;43:252-9
   PubMed Web of Science ®Google Scholar
• Thompson-Culkin K, Zussman B, Miller AK, Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. J Int Med Res 2002;30:391-9
   PubMed Web of Science ®Google Scholar
• Aramwit P, Supasyndh O, Sriboonruang T. Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients. J Clin Pharm Ther 2008;33:685-90
   PubMed Web of Science ®Google Scholar
• Agrawal A, Sautter MC, Jones NP. Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis. Clin Ther 2003;25:2754-64
   PubMed Web of Science ®Google Scholar
• Wong TY, Szeto CC, Chow KM, Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 2005;46:713-19
   PubMed Web of Science ®Google Scholar
• Chiang CK, Ho TI, Peng YS, Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. Diabetes Care 2007;30:3-7
   PubMed Web of Science ®Google Scholar
• Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother 2012;13:81-99
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-58
   PubMed Web of Science ®Google Scholar
• Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet 2012;51:501-14
   PubMed Web of Science ®Google Scholar
• Mikhail N. Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease. Postgrad Med 2012;124:138-44
   PubMed Web of Science ®Google Scholar
• Bergman AJ, Cote J, Yi B, Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007;30:1862-4
   PubMed Web of Science ®Google Scholar
• He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet 2012;51:147-62
   PubMed Web of Science ®Google Scholar
• He YL, Kulmatycki K, Zhang Y, Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment. Int J Clin Pharmacol Ther 2013; In press
   Web of Science ®Google Scholar
• Boulton DW, Li L, Frevert EU, Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011;50:253-65
   PubMed Web of Science ®Google Scholar
• Karim A, Fleck P, Hetman L, Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment. Diabetes 2008;57(Suppl 1):A160; 538-P
   Google Scholar
• Nowicki M, Rychlik I, Haller H, Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011;65:1230-9
   PubMed Web of Science ®Google Scholar
• Chan JC, Scott R, Arjona Ferreira JC, Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545-55
   PubMed Web of Science ®Google Scholar
• Lukashevich V, Schweizer A, Shao Q, Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 2011;13:947-54
   PubMed Web of Science ®Google Scholar
• Kothny W, Shao Q, Groop PH, One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal insufficiency. Diabetes Obes Metab 2012;14:1032-9
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Exp Opin Drug Metab Toxicol 2011;7:1561-76
   PubMed Web of Science ®Google Scholar
• Cooper M VEM, Emser A, Patel S, Wörle HJ. Efficacy and safety of linagliptin in patients with type 2 diabetes with or without renal impairment: results from a global Phase 3 program. Diabetes 2011;60:abstract 1068-P
   Google Scholar
• McGill JB, Sloan L, Newman J, Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2013;36:237-44
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Expert Opin Drug Metab Toxicol 2010;6:1265-76
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. Expert Opin Drug Metab Toxicol 2012;8:383-94
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Efficacy and safety of Jentadueto (linagliptin plus metformin). Expert Opin Drug Safety 2013;12(2):275-89
   PubMed Web of Science ®Google Scholar
• Banerji MA, Purkayastha D, Francis BH. Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study. Diabetes Res Clin Pract 2010;90:182-90
   PubMed Web of Science ®Google Scholar
• Ligueros-Saylan M, Foley JE, Schweizer A, An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab 2010;12:495-509
   PubMed Web of Science ®Google Scholar
• Ito M, Abe M, Okada K, The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J 2011;58:979-87
   PubMed Web of Science ®Google Scholar
• Lukashevich V, Schweizer A, Foley JE, Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag 2013;9:21-8
   PubMedGoogle Scholar
• Nowicki M, Rychlik I, Haller H, Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011;13:523-32
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U, Friedrich C, Port A, Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011;13:939-46
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Expert Opin Drug Metab Toxicol 2011;7:1561-76
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010;70:377-85
   PubMed Web of Science ®Google Scholar
• Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 2012;72:2289-312
   PubMed Web of Science ®Google Scholar
• Macha S, Dieterich S, Mattheus M, Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers. Int J Clin Pharmacol Ther 2013;51:132-40
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Liu X, Benito MP, The influence of kidney function on dapagliflozin exposure, metabolism, and efficacy in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol 2012; published on line 2012/12/06; doi: 10.1111/bcp.12056
   Web of Science ®Google Scholar
• Weise WJ, Sivanandy MS, Block CA, Exenatide-associated ischemic renal failure. Diabetes Care 2009;32:e22-3
   PubMedGoogle Scholar
• Lopez-Ruiz A, del Peso-Gilsanz C, Meoro-Aviles A, Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers. Pharm World Sci 2010;32:559-61
   PubMed Web of Science ®Google Scholar
• Kaakeh Y, Kanjee S, Boone K, Liraglutide-induced acute kidney injury. Pharmacotherapy 2012;32:e7-11
   PubMed Web of Science ®Google Scholar
• Pendergrass M, Fenton C, Haffner SM, Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes Obes Metab 2012;14:596-600
   PubMed Web of Science ®Google Scholar
• Linnebjerg H, Kothare PA, Park S, Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007;64:317-27
   PubMed Web of Science ®Google Scholar
• Jacobsen LV, Hindsberger C, Robson R, Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009;68:898-905
   PubMed Web of Science ®Google Scholar
• Davidson JA, Brett J, Falahati A, Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract 2011;17:345-55
   PubMed Web of Science ®Google Scholar
• Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia 1984;27:351-7
   PubMed Web of Science ®Google Scholar
• Runyan JW Jr, Hurwitz D, Robbins SL. Effect of Kimmelstiel-Wilson syndrome on insulin requirements in diabetes. N Engl J Med 1955;252:388-91
   PubMed Web of Science ®Google Scholar
• Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004;17:365-70
   PubMed Web of Science ®Google Scholar
• Biesenbach G, Raml A, Schmekal B, Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients. Diabet Med 2003;20:642-5
   PubMed Web of Science ®Google Scholar
• Morello CM. Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus. Int J Gen Med 2011;4:827-35
   PubMedGoogle Scholar
• Rave K, Heise T, Pfutzner A, Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care 2001;24:886-90
   PubMed Web of Science ®Google Scholar
• Czock D, Aisenpreis U, Rasche FM, Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus. Int J Clin Pharmacol Ther 2003;41:492-7
   PubMed Web of Science ®Google Scholar
• Holmes G, Galitz L, Hu P, Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol 2005;60:469-76
   PubMed Web of Science ®Google Scholar
• Baldwin D, Zander J, Munoz C, A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care 2012;35:1970-4
   PubMed Web of Science ®Google Scholar
• Ersoy A, Ersoy C, Altinay T. Insulin analogue usage in a haemodialysis patient with type 2 diabetes mellitus. Nephrol Dial Transplant 2006;21:553-4
   PubMed Web of Science ®Google Scholar
• McGavin JK, Perry CM, Goa KL. Gliclazide modified release. Drugs 2002;62:1357-64; discussion 65-6
   PubMed Web of Science ®Google Scholar